Results 41 to 50 of about 33,041 (261)
Cancer Drug Resistance, 2021 Aim: Anti-CD20 monoclonal antibody is a cornerstone therapy for follicular lymphoma. Following anti-CD20 therapy, a potential decrease in CD20 antigen, and therefore a loss of the tumor target might be expected. However, the incidence and clinical significance of CD20 loss on tumor cells in patients with relapsed or refractory follicular lymphoma are ...
Michot, Jean-Marie +15 more
openaire +3 more sources
Lymphoid‐Tissue‐on‐Chip Recapitulates Human Antibody Responses In Vitro
Advanced Science, EarlyView.The presented lymphoid‐tissue‐on‐chip system allows culture of primary human tonsil cells at organotypic high density under perfusion for up to 4 weeks, emulates immune response to soluble vaccines and vaccination via peripheral antigen‐presenting cells and represents a useful tool to assess cellular interactions during homeostasis, immune responses ...
Claudia Teufel +15 more
wiley +1 more source
Probing the sensitivity of autoantibody production to B cell depletion by Rituximab [PDF]
, 2010 Rituximab, a monoclonal antibody directed against the human CD20 antigen, causes profound depletion of all B cells. When used in patients with autoimmune disease, IgG autoantibody titres often fall whilst serum IgG anti-tetanus toxoid antibody titres are
Ferraro, Alastair James
core
, 2019 International audiencePreclinical and clinical studies have suggested that cancer treatment with antitumor antibodies induces a specific adaptive T cell response. A central role in this process has been attributed to CD4+ T cells, but the relevant T cell
Josseaume, Nathalie +19 more
core +1 more source
Advanced Science, EarlyView.ABSTRACT Despite the transformative impact of cancer immunotherapies such as immune checkpoint blockade, durable clinical responses remain limited. Increasing evidence indicates that antitumor immunity is governed not only by the tumor microenvironment, but also by systemic immune regulation mediated by peripheral immune organs. Among these, the spleen
Yuehua Liu, Xiaoqian Nie, Xiaofei Gao
wiley +1 more source
CAQ Corner: Immune‐mediated complications
, 2022 Liver Transplantation, EarlyView.
Mary Thomson, John R. Lake
wiley +1 more source
Adaptive immunity in cancer immunology and therapeutics.
, 2014 Copyright: © the authors; licensee ecancermedicalscience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
Spurrell, EL, Lockley, M
core +1 more source
A Catalytic Osmium Redox Couple Collapses Cancer Redox Balance
Advanced Science, EarlyView.A stable Os(III)/Os(IV) redox couple is developed to disrupt the tumor cell redox balance by concurrently catalyzing ROS generation and GSH depletion. Osmium‐treated cells exhibit multiple cell death pathways, including apoptosis, ferroptosis, and immunogenic cell death.
Wan‐Qiong Huang +9 more
wiley +1 more source
, 2015 Results presented as average ± standard deviation. N = 2 for rituximab, N = 3 for HH1.Maximum number of CD37 and CD20 antigens (Bmax) and equilibrium dissociation constant (Kd) of 177Lu-HH1 and 125I-rituximab in Ramos cells.
Roy H. Larsen (605499) +7 more
core +1 more source
Reprogramming the Immune Landscape of Inflammatory Breast Cancer
Advanced Science, EarlyView.Inflammatory breast cancer is the most lethal subtype of breast cancer and is characterized by an immunosuppressive tumor microenvironment (TME) driven by a complex network of immune cells and inflammatory cytokines, contributing to its aggressiveness and treatment challenges. Immune checkpoint inhibitors, either alone or in combination, show potential
Verena Martinez‐Rodriguez +3 more
wiley +1 more source